Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2875358 plus erlotinib versus erlotinib after erlotinib lead-in in EGFR-mutant metastatic NSCLC
NL-OMON44916Phase 2Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2014
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of emibetuzumab and erlotinib in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Started Apr 2014; status: recruiting.
02
Drugs
emibetuzumaberlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON44916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44916.